Peer-reviewedCC BYMolecular therapy. Nucleic acids
CasNano: An ultracompact CRISPR-Cas12f with a GC-rich PAM for epigenome editing with therapeutic potential
- 1Epitor Therapeutics, Inc., New York, NY 10032, USA
- 2Department of Physiology and Cellular Biophysics, Columbia University, New York, NY 10032, USA
- 3Department of Medicine and Department of Systems Biology, New York, NY 10032, USA
Related
- Programming plant resilience with CRISPR/dCas9 epigenome editing: from proof of concept to crop deployment
- Epigenome editing in animal production: a prospective review
- Beyond DNA—CRISPR technologies for epigenome editing and transcriptional regulation in disease: A scoping review
- The Gut Microbiota–Epigenome Axis in Bariatric Surgery: Mechanistic Insights and Therapeutic Perspectives
- Skin-Derived Non-Coding RNAs as Potential Biomarkers and Therapeutic Targets
BibTeX
@article{kim2026casnano,
title = {{CasNano: An ultracompact CRISPR-Cas12f with a GC-rich PAM for epigenome editing with therapeutic potential}},
author = {Dongkyeong Kim and Chia-Wei Huang and Richard Pan and Junming Qian and Xuebing Wu and Orrin Devinsky and Yi-Ting Tsai and Shawn Liu},
journal = {Molecular therapy. Nucleic acids},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13670948},
note = {CC BY},
}
RIS
TY - JOUR
TI - CasNano: An ultracompact CRISPR-Cas12f with a GC-rich PAM for epigenome editing with therapeutic potential
AU - Dongkyeong Kim
AU - Chia-Wei Huang
AU - Richard Pan
AU - Junming Qian
AU - Xuebing Wu
AU - Orrin Devinsky
AU - Yi-Ting Tsai
AU - Shawn Liu
PY - 2026
DA - 2026/09/18
JO - Molecular therapy. Nucleic acids
UR - https://europepmc.org/article/PMC/PMC13670948
SN - 2162-2531
ER -